Format

Send to

Choose Destination
Curr Cardiol Rep. 2017 Mar;19(3):25. doi: 10.1007/s11886-017-0832-3.

Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?

Author information

1
MedStar Health Research Institute, 6525 Belcrest Road, Suite #700, Hyattsville, MD, 20782, USA.
2
MedStar Health Research Institute, 6525 Belcrest Road, Suite #700, Hyattsville, MD, 20782, USA. vanita.aroda@medstar.net.
3
Georgetown University School of Medicine, Washington, DC, USA. vanita.aroda@medstar.net.

Abstract

PURPOSE OF REVIEW:

Guidelines for a standard second diabetes medication for the treatment of type 2 diabetes (T2DM) have yet to be established. The rapid increase in the number of newer therapies available makes the choice more difficult. Thus, we reviewed clinical trial evidence evaluating newer therapies available for treatment intensification beyond monotherapy.

RECENT FINDINGS:

Head-to-head studies comparing newer therapies versus traditional (i.e., sulfonylurea) approaches consistently find lower incidence of hypoglycemia and weight gain with newer therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrate high glycemic efficacy, while merits of dipeptidyl peptidase-4 (DPP-4) inhibitors include their tolerability. Secondary effects (weight loss, cardiovascular outcomes, renal function) are of growing interest with newer therapies. Choices for treatment intensification in T2DM diabetes are numerous. Understanding the comparative evidence of newer treatment choices, as provided in this review, may help guide clinical decision making.

KEYWORDS:

DPP-4 inhibitors; GLP-1 receptor agonists; Intensification after monotherapy; SGLT-2 inhibitors; Type 2 diabetes

PMID:
28251513
DOI:
10.1007/s11886-017-0832-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center